Trial Profile

A Phase 2 Study to Assess the Safety, Tolerability, and Activity of BGB-3111 in Combination With Rituximab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Non-GCB Subtype) and Relapsed/Refractory Indolent Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 30 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zanubrutinib (Primary) ; Rituximab
Indications B-cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma
Focus Adverse reactions; Therapeutic Use
Sponsors BeiGene

28 Sep 2020 Status changed from active, no longer recruiting to completed.
21 Jun 2020 Results (n=41) presented at the 25th Congress of the European Haematology Association.
12 Jun 2020 According to an BeiGene media release, pooled analysis from 4 studies (NCT04170283; NCT03145064; NCT02569476; NCT03520920) were presented at the 25th European Hematology Association (EHA) Virtual Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com